Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Femasys (FEMY)
NASDAQ:FEMY
Holding FEMY?
Track your performance easily
FEMY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.73 - $2.40
Previous Close$1.09
Volume79.72K
Average Volume (3M)180.54K
Market Cap
$25.19M
Enterprise Value$22.65M
Total Cash (Recent Filing)$7.61M
Total Debt (Recent Filing)$5.07M
Price to Earnings (P/E)―
Beta-1.56
Next Earnings
Mar 27, 2025EPS Estimate
-$0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding22,898,468
10 Day Avg. Volume371,025
30 Day Avg. Volume180,541
Standard Deviation0.96
R-Squared0.02
Alpha0.11
Financial Highlights & Ratios
Price to Book (P/B)4.19
Price to Sales (P/S)20.15
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue17.53
Enterprise Value/Gross Profit32.73
Enterprise Value/Ebitda-1.46
Forecast
1Y Price Target
$7.67Price Target Upside603.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Femasys News
PremiumCompany Announcements
Femasys Advances in Women’s Health Innovation
Bulls Say, Bears Say
Bulls Say
Market ExpansionPartnership with HRC Fertility provides Femasys with an additional direct sight of potential revenues, as physicians will now be offering FemaSeed to couples with infertility.
Product Launch SuccessInitial sales of FemaSeed were higher than initial estimates, showcasing positive initial launch efforts.
Regulatory ApprovalsThe company has received the European Union Medical Device Regulation (EU MDR) certificate and CE Mark certification for FemaSeed, FemVue, FemCerv, and FemCath, providing regulatory approval to begin marketing these products in the European Union.
Bears Say
Business RisksRisks include safety signals, lower-than-expected efficacy from clinical programs, greater-than-expected commercial competition, regulatory concerns, and financing requirements for the business.
Cash ReservesThe company ended the quarter with cash and equivalents of $13.5 million compared to $21.7 million at the end of the previous fiscal year.
Dilution ConcernsThe lower price target reflects a higher projected future share count as modeled future capital raises are expected to be more dilutive due to the decline in share price.
---
Ownership Overview
5.39%
Insiders
1.62% Mutual Funds
4.67% Other Institutional Investors
84.71% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
FEMY FAQ
What was Femasys’s price range in the past 12 months?
Femasys lowest stock price was $0.73 and its highest was $2.40 in the past 12 months.
What is Femasys’s market cap?
Currently, no data Available
When is Femasys’s upcoming earnings report date?
Femasys’s upcoming earnings report date is Mar 27, 2025 which is in 96 days.
How were Femasys’s earnings last quarter?
Femasys released its earnings results on Nov 12, 2024. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.2 by -$0.04.
Is Femasys overvalued?
According to Wall Street analysts Femasys’s price is currently Undervalued.
Does Femasys pay dividends?
Femasys does not currently pay dividends.
What is Femasys’s EPS estimate?
Femasys’s EPS estimate is -$0.18.
How many shares outstanding does Femasys have?
Femasys has 22,898,468 shares outstanding.
What happened to Femasys’s price movement after its last earnings report?
Femasys reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.2. Following the earnings report the stock price went down -11.207%.
Which hedge fund is a major shareholder of Femasys?
Currently, no hedge funds are holding shares in FEMY
---
Femasys Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (603.67% Upside)
$7.67 (603.67% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
23.44%
12-Months-Change
Fundamentals
Return on Equity
-220.59%
Trailing 12-Months
Asset Growth
4.92%
Trailing 12-Months
Company Description
Femasys
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. Its mission is to provide women with minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
---
FEMY Stock 12 Month Forecast
Average Price Target
$7.67
▲(603.67% Upside)
Technical Analysis
Best Analysts Covering FEMY
1 Year
1 Year Success Rate
9/14 ratings generated profit
1 Year Average Return
+18.67%
reiterated a buy rating last month
Copying Keay Nakae's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +18.67% per trade.
---